G-protein-coupled receptor 84 (GPR84) is an orphan G protein-coupled receptor (GPCR) mainly expressed in immune cells involved in inflammation, metabolic disorders, and cancer.
Calluna Pharma Inc., formed last year following the merger of Oxitope Pharma BV and Arxx Therapeutics AS, has raised €75 million (US$81.4 million) in a series A financing.
Mutant huntingtin (HTT) protein is the main cause of the pathological features leading to Huntington's disease (HD) development, a neurological disorder characterized by CAG repeat expansion in exon 1 of the HTT gene, which causes neuronal dysfunction and death along the brain.
Researchers from Broad Institute and Harvard University presented the discovery of all-in-one virus-like particles (VLPs) designed to deliver prime editor (PE) ribonucleoprotein (RNP) complexes into mammalian cells.
Naegleria fowleri, colloquially known as the "brain-eating amoeba," is a water-borne amoeba and the leading cause of primary amoebic meningoencephalitis (PAM). In a recent study published in Scientific Reports, researchers from the University of Central Punjab aimed to design an mRNA-based vaccine against PAM.
IMU Biosciences Ltd. has raised £11.5 million (US$14.7 million) in a series A round to further develop and commercialize profiling technology that can identify from a blood sample which of more than 2,000 cell types are present in an individual’s immune system.
RSS
